Primary biliary cirrhosis secondary prevention
|
Primary Biliary Cirrhosis Microchapters |
|
Differentiating Primary Biliary Cirrhosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary biliary cirrhosis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Primary biliary cirrhosis secondary prevention |
|
Risk calculators and risk factors for Primary biliary cirrhosis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dildar Hussain, MBBS [2]
Overview
Effective measures for the secondary prevention of primary biliary cirrhosis include follow up with liver function tests , thyroid status , upper GI endoscopy, bone mineral density, fat-soluble vitamin levels, ultrasound and alpha-fetoprotein levels to screen for hepatocellular carcinoma among aged men and patients with underlying cirrhosis.
Secondary Prevention
- Effective measures for the secondary prevention of primary biliary cirrhosis include:[1][2][3]
- Follow up with liver function tests every 3 to 6 months.
- Follow up with thyroid status annually.
- Follow up with upper GI endoscopy to assess for development of varices every 2-3 years.
- Follow up with bone mineral density every 2-4 years, depending upon the baseline density and severity of cholestasis.
- Follow up with fat-soluble vitamin levels (Vitamin A,D&K) annually in patients with bilirubin >2mg/dl.
- Follow up with ultrasound and alpha-fetoprotein levels to screen for hepatocellular carcinoma every 6 to 12 months among aged men and patients with underlying cirrhosis.
References
- ↑ Chazouillères O, Wendum D, Serfaty L, Rosmorduc O, Poupon R (2006). "Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome". J. Hepatol. 44 (2): 400–6. doi:10.1016/j.jhep.2005.10.017. PMID 16356577.
- ↑ Poupon, Raoul; Chazouilleres, Olivier; Corpechot, Christophe; Chrétien, Yves (2006). "Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis". Hepatology. 44 (1): 85–90. doi:10.1002/hep.21229. ISSN 0270-9139.
- ↑ Nezu S, Tanaka A, Yasui H, Imamura M, Nakajima H, Ishida H, Takahashi S (2006). "Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis". J. Gastroenterol. Hepatol. 21 (9): 1448–54. doi:10.1111/j.1440-1746.2006.04434.x. PMID 16911691.